CDK11A
Basic information
Region (hg38): 1:1702379-1724357
Previous symbols: [ "CDC2L3", "CDC2L2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (102 variants)
- not_provided (10 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CDK11A gene is commonly pathogenic or not. These statistics are base on transcript: NM_000024011.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 5 | |||||
| missense | 101 | 104 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 2 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 103 | 8 | 0 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| CDK11A | protein_coding | protein_coding | ENST00000404249 | 19 | 21598 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 1.38e-17 | 0.0112 | 124054 | 4 | 583 | 124641 | 0.00236 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -0.828 | 339 | 299 | 1.13 | 0.0000188 | 5028 |
| Missense in Polyphen | 54 | 63.928 | 0.8447 | 1211 | ||
| Synonymous | -3.12 | 163 | 120 | 1.36 | 0.00000791 | 1336 |
| Loss of Function | 0.316 | 27 | 28.8 | 0.936 | 0.00000155 | 525 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.00125 | 0.00125 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000224 | 0.000223 |
| Finnish | 0.0123 | 0.0121 |
| European (Non-Finnish) | 0.00197 | 0.00189 |
| Middle Eastern | 0.000224 | 0.000223 |
| South Asian | 0.00206 | 0.00196 |
| Other | 0.00291 | 0.00281 |
dbNSFP
Source:
- Function
- FUNCTION: Appears to play multiple roles in cell cycle progression, cytokinesis and apoptosis. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression. {ECO:0000269|PubMed:12501247, ECO:0000269|PubMed:12624090}.;
- Pathway
- terminal <i>O</i>-glycans residues modification;Recruitment of mitotic centrosome proteins and complexes;Centrosome maturation;G2/M Transition;Mitotic G2-G2/M phases;Cell Cycle;Cell Cycle, Mitotic
(Consensus)
Recessive Scores
- pRec
- 0.141
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.370
- ghis
- 0.519
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.781
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | High | High | High |
| Primary Immunodeficiency | High | High | High |
| Cancer | High | High | High |
Gene ontology
- Biological process
- mitotic cell cycle;regulation of cell growth;regulation of transcription, DNA-templated;protein phosphorylation;apoptotic process;regulation of mRNA processing;regulation of cell cycle
- Cellular component
- nucleus;cytoplasm
- Molecular function
- protein kinase activity;protein serine/threonine kinase activity;cyclin-dependent protein serine/threonine kinase activity;ATP binding